Recent advance in immunological tests in paraneoplastic neurological syndrome.
Paraneoplastic neurological syndromes are uncommon, however; their diagnosis is of major practical importance. Any portion of the nervous system may be involved in paraneoplastic syndromes. There is increasing evidence that the pathogenesis of many paraneoplastic neurological syndromes appears to be an immune reaction against antigen shared by the cancer and the nervous system. The identification of antibodies in the serum or cerebrospinal fluid in the central nervous system of paraneoplastic syndrome patient confirms the clinical diagnosis of paraneoplastic syndrome, and allows early identification of an underlying tumor at a stage when it is localized and more amenable to treatment. Cancer therapy (surgery, radiotherapy, chemotherapy) seems to be the most efficient treatment for the paraneoplastic neurological symptoms. Immunomodulatory therapy (intravenous immunoglobulin, plasmapheresis, immunosuppression) can halt or even reverse the neurological syndrome. The recent advances in understanding of the autoimmune pathology of these disorders should lead to more effective treatment options.
Fong
Chin-Shih
CS
Department of Neurology, Buddhist Dalin Tzu Chi General Hospital, Chia Yi, Taiwan. csfong@seed.net.tw
D001323:Autoantibodies / Q000097:blood; D004679:Encephalomyelitis / Q000276:immunology; D006801:Humans; D007159:Immunologic Tests; D015624:Lambert-Eaton Myasthenic Syndrome / Q000276:immunology; D015835:Ocular Motility Disorders / Q000276:immunology; D020362:Paraneoplastic Cerebellar Degeneration / Q000276:immunology; D020361:Paraneoplastic Syndromes, Nervous System / Q000175:diagnosis / Q000209:etiology / Q000276:immunology* / Q000628:therapy; D016750:Stiff-Person Syndrome / Q000276:immunology
D001323:Autoantibodies